메뉴 건너뛰기




Volumn 12, Issue 4, 2011, Pages 445-447

SNPs in ERCC1 and drug response to cisplatin in non-small-cell lung cancer patients

Author keywords

cisplatin; ERCC1; SNP

Indexed keywords

CISPLATIN; DNA; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; NAVELBINE; PACLITAXEL;

EID: 79955536718     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.15     Document Type: Editorial
Times cited : (7)

References (21)
  • 1
    • 78049423379 scopus 로고    scopus 로고
    • Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer
    • Li F, Sun X, Sun N et al.: Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am. J. Clin. Oncol. 33, 489-494 (2010).
    • (2010) Am. J. Clin. Oncol. , vol.33 , pp. 489-494
    • Li, F.1    Sun, X.2    Sun, N.3
  • 2
    • 77956188702 scopus 로고    scopus 로고
    • The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis
    • Chen S, Zhang J, Wang R et al.: The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70, 63-70 (2010).
    • (2010) Lung Cancer , vol.70 , pp. 63-70
    • Chen, S.1    Zhang, J.2    Wang, R.3
  • 3
    • 0038350391 scopus 로고    scopus 로고
    • Genetic testing for chemotherapy in non-small cell lung cancer
    • DOI 10.1016/S0169-5002(03)00151-X
    • Rosell R, Taron M, Alberola V et al.: Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 41, S97-S102 (2003). (Pubitemid 36819001)
    • (2003) Lung Cancer , vol.41 , Issue.SUPPL. 1
    • Rosell, R.1    Taron, M.2    Alberola, V.3    Massuti, B.4    Felip, E.5
  • 4
    • 79955525769 scopus 로고    scopus 로고
    • No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: A meta-analysis
    • Epub ahead of print
    • Yin M, Yan J, Voutsina A et al.: No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer (2010) (Epub ahead of print).
    • (2010) Lung Cancer
    • Yin, M.1    Yan, J.2    Voutsina, A.3
  • 5
    • 0011511768 scopus 로고    scopus 로고
    • Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs
    • Alison MR (Ed.). Nature Publishing Group, London, UK
    • Siddik ZH: Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. In: The Cancer Handbook. Alison MR (Ed.). Nature Publishing Group, London, UK, 1295-1313 (2002).
    • (2002) The Cancer Handbook , pp. 1295-1313
    • Zh, S.1
  • 6
    • 78650944117 scopus 로고    scopus 로고
    • Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine
    • Viñolas N, Provencio M, Reguart N et al.: Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 71, 191-198 (2011).
    • (2011) Lung Cancer , vol.71 , pp. 191-198
    • Viñolas, N.1    Provencio, M.2    Reguart, N.3
  • 7
    • 0346238665 scopus 로고    scopus 로고
    • Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
    • DOI 10.1056/NEJMoa031644
    • Arriagada R, Bergman B, Dunant A et al.; The International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350, 351-360 (2004). (Pubitemid 38101630)
    • (2004) New England Journal of Medicine , vol.350 , Issue.4 , pp. 351-360
    • Arriagada, R.1    Bergman, B.2    Dunant, A.3    Le Chevalier, T.4    Pignon, J.-P.5    Vansteenkiste, J.6
  • 8
    • 0036732039 scopus 로고    scopus 로고
    • Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells
    • Furuta T, Ueda T, Aune G et al.: Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 62, 4899-4902 (2002). (Pubitemid 34984411)
    • (2002) Cancer Research , vol.62 , Issue.17 , pp. 4899-4902
    • Furuta, T.1    Ueda, T.2    Aune, G.3    Sarasin, A.4    Kraemer, K.H.5    Pommier, Y.6
  • 16
    • 77957696698 scopus 로고    scopus 로고
    • Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients
    • Zhou C, Ren S, Zhou S et al.: Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn. J. Clin. Oncol. 40, 954-960 (2010).
    • (2010) Jpn. J. Clin. Oncol. , vol.40 , pp. 954-960
    • Zhou, C.1    Ren, S.2    Zhou, S.3
  • 17
    • 65349117547 scopus 로고    scopus 로고
    • DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer
    • Kalikaki A, Kanaki M, Vassalou H et al.: DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin. Lung Cancer 10, 118-123 (2009).
    • (2009) Clin. Lung Cancer , vol.10 , pp. 118-123
    • Kalikaki, A.1    Kanaki, M.2    Vassalou, H.3
  • 18
    • 79952251471 scopus 로고    scopus 로고
    • Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: A systematic review and meta-analysis
    • Wei SZ, Zhan P, Shi MQ et al.: Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med. Oncol. 28(1), 315-321 (2011).
    • (2011) Med. Oncol. , vol.28 , Issue.1 , pp. 315-321
    • Wei, S.Z.1    Zhan, P.2    Shi, M.Q.3
  • 20
    • 71549134934 scopus 로고    scopus 로고
    • Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients
    • Takenaka T, Yano T, Kiyohara C et al.: Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 67, 101-107 (2010).
    • (2010) Lung Cancer , vol.67 , pp. 101-107
    • Takenaka, T.1    Yano, T.2    Kiyohara, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.